Addex Therapeutics Files 6-K, Incorporates Exhibits
Ticker: ADXN · Form: 6-K · Filed: Nov 22, 2024 · CIK: 1574232
Sentiment: neutral
Topics: filing, registration
TL;DR
Addex Therapeutics filed a 6-K, incorporating exhibits into its S-8 filings. Standard procedure.
AI Summary
Addex Therapeutics Ltd. filed a Form 6-K on November 22, 2024, incorporating Exhibits 99.1 and 99.2 into its existing S-8 registration statements (Registration Nos. 333-255124 and 333-272515). The filing is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. The company is based in Geneva, Switzerland.
Why It Matters
This filing incorporates previously released information into SEC registration statements, which is a standard procedural step for companies with outstanding equity registrations.
Risk Assessment
Risk Level: low — This filing is primarily procedural and does not introduce new material risks or significant business updates.
Key Players & Entities
- Addex Therapeutics Ltd. (company) — Registrant
- 333-255124 (dollar_amount) — S-8 Registration Number
- 333-272515 (dollar_amount) — S-8 Registration Number
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to report information as a Foreign Private Issuer and to incorporate Exhibits 99.1 and 99.2 into Addex Therapeutics Ltd.'s existing S-8 registration statements.
Which registration statements are being updated by this filing?
Exhibits 99.1 and 99.2 are being incorporated by reference into the registration statements on Form S-8, specifically Registration No. 333-255124 and No. 333-272515.
What is the principal executive office address of Addex Therapeutics Ltd.?
The principal executive offices are located at Chemin des Mines 9, CH-1202 Geneva, Switzerland.
Under which rules is this Form 6-K filed?
This Form 6-K is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
What is the SIC code for Addex Therapeutics Ltd.?
The Standard Industrial Classification (SIC) code for Addex Therapeutics Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 398 words · 2 min read · ~1 pages · Grade level 12.5 · Accepted 2024-11-22 06:00:13
Filing Documents
- tm2429141d1_6k.htm (6-K) — 17KB
- tm2429141d1_ex99-1.htm (EX-99.1) — 782KB
- tm2429141d1_ex99-2.htm (EX-99.2) — 194KB
- tm2429141d1_ex99-3.htm (EX-99.3) — 57KB
- tm2429141d1_ex99-3img001.jpg (GRAPHIC) — 11KB
- 0001104659-24-121730.txt ( ) — 1066KB
RISK FACTORS
RISK FACTORS Our business faces significant risks. You should carefully consider all of the information set forth in this Report on Form 6-K and in our other filings with the United States Securities and Exchange Commission, or the SEC, including the risk factors related to our business set forth in our Annual Report on Form 20-F for the year ended December 31, 2023 filed with the Securities and Exchange Commission on April 18, 2024 and updated in our prospectus (No.333-271611) amended on April 24, 2024. Our business, financial condition, results of operations and growth prospects could be materially adversely affected by any of these risks. This report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of certain factors including the risks described in our Annual Report and our other SEC filings. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Addex Therapeutics Ltd By: /s/ Tim Dyer Name: Tim Dyer Date: November 22, 2024 Title: Chief Executive Officer 3 EXHIBIT INDEX Exhibit No. Description Exhibit 99.1 : Unaudited interim Condensed Consolidated Financial Statements Exhibit 99.2 : Management’s Discussion and Analysis of Financial Condition and Results of Operations Exhibit 99.3 : Press Release dated November 22, 2024 4